Renal Function in Glycogen Storage Disease Type I, Natural Course, and Renopreservative Effects of ACE Inhibition

被引:31
作者
Martens, Danielle H. J. [1 ]
Rake, Jan Peter [2 ]
Navis, Gerjan [3 ]
Fidler, Vaclav [4 ]
van Dael, Catharina M. L. [5 ]
Smit, G. Peter A. [1 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat, NL-9700 RB Groningen, Netherlands
[2] Martini Hosp Groningen, Dept Pediat, Groningen, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Nephrol, NL-9700 RB Groningen, Netherlands
[4] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9700 RB Groningen, Netherlands
[5] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat Nephrol, NL-9700 RB Groningen, Netherlands
来源
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2009年 / 4卷 / 11期
关键词
DIABETIC-NEPHROPATHY; BLOOD-PRESSURE; ESGSD-I; MANAGEMENT; CHILDREN;
D O I
10.2215/CJN.00050109
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives: Renal failure is a major complication in glycogen storage disease type I (GSD I). We studied the natural course of renal function in GSD I patients. We studied differences between patients in optimal and nonoptimal metabolic control and possible renoprotective effects of angiotensin converting enzyme inhibition. Design, setting, participants, & measurements: Thirty-nine GSD I patients that visited our clinic were studied. GFR and effective renal plasma flow (ERPF) were measured by means of I-125 iothalamate and I-131 hippuran clearance and corrected for body surface area. Microalbuminuria was defined as >2.5 mg albumin/mmol creatinine and proteinuria as >0.2 g protein per liter. Optimal metabolic control was present when blood glucoses were >3.5 mmol/L, urine lactate/creatinine ratios <0.06 mmol/mmol, triglycerides <6.0 mmol/L, and uric acid concentrations <450 mu mol/L. Results: Quadratic regression analysis showed a biphasic pattern in the course of GFR and ERPF related to age. Microalbuminuria was observed significantly less frequently in the patients with optimal metabolic control compared with the patients with nortoptimal metabolic control. A significant decrease in GFR was observed after starting ACE inhibition. Conclusions: This study describes a biphasic pattern of the natural course of GFR and ERPF in GSD I patients, followed by the development of microalbuminuria and proteinuria. Optimal metabolic control has a renoprotective effect on the development of microalbuminuria and proteinuria in GSD I patients. Treatment with ACE inhibitors significantly decreases the GFR especially in GSD I patients with glomerular hyperfiltration. Clin J Ant Soc Nephrol 4: 1741-1746, 2009. doi: 10.2215/CJN.00050109
引用
收藏
页码:1741 / 1746
页数:6
相关论文
共 40 条
  • [1] Progressive development of renal cysts in glycogen storage disease type I
    Gjorgjieva, Monika
    Raffin, Margaux
    Duchampt, Adeline
    Perry, Ariane
    Stefanutti, Anne
    Brevet, Marie
    Tortereau, Antonin
    Dubourg, Laurence
    Hubert-Buron, Aurelie
    Mabille, Mylene
    Pelissou, Coralie
    Lassalle, Louis
    Labrune, Philippe
    Mithieux, Gilles
    Rajas, Fabienne
    HUMAN MOLECULAR GENETICS, 2016, 25 (17) : 3784 - 3797
  • [2] Glycogen storage disease type I a: Frequency and clinical course in Turkish children
    Saltik I.N.
    Özen H.
    Ciliv G.
    Koçak N.
    Yüce A.
    Gürakan F.
    Dinler G.
    The Indian Journal of Pediatrics, 2000, 67 (7) : 497 - 501
  • [3] Liver transplantation in glycogen storage disease type I
    Boers, Susanna J. B.
    Visser, Gepke
    Smit, Peter G. P. A.
    Fuchs, Sabine A.
    ORPHANET JOURNAL OF RARE DISEASES, 2014, 9
  • [4] Natural History of Hepatocellular Adenoma Formation in Glycogen Storage Disease Type I
    Wang, David Q.
    Fiske, Laurie M.
    Carreras, Caroline T.
    Weinstein, David A.
    JOURNAL OF PEDIATRICS, 2011, 159 (03) : 442 - 446
  • [5] Dietary dilemmas in the management of glycogen storage disease type I
    Bhattacharya, Kaustuv
    JOURNAL OF INHERITED METABOLIC DISEASE, 2011, 34 (03) : 621 - 629
  • [6] Menorrhagia in Patients With Type I Glycogen Storage Disease
    Austin, Stephanie L.
    El-Gharbawy, Areeg H.
    Kasturi, Vellore G.
    James, Andra
    Kishnani, Priya S.
    OBSTETRICS AND GYNECOLOGY, 2013, 122 (06) : 1246 - 1254
  • [7] Hypovitaminosis D in glycogen storage disease type I
    Banugaria, Suhrad G.
    Austin, Stephanie L.
    Boney, Anne
    Weber, Thomas J.
    Kishnani, Priya S.
    MOLECULAR GENETICS AND METABOLISM, 2010, 99 (04) : 434 - 437
  • [8] Emerging therapies for glycogen storage disease type I
    Koeberl, D. D.
    Kishnani, P. S.
    Bali, D.
    Chen, Y-T.
    TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2009, 20 (05) : 252 - 258
  • [9] Psychosocial functioning in youth with glycogen storage disease type I
    Storch, Eric
    Keeley, Mary
    Merlo, Lisa
    Jacob, Marni
    Correia, Catherine
    Weinstein, David
    JOURNAL OF PEDIATRIC PSYCHOLOGY, 2008, 33 (07) : 728 - 738
  • [10] Renal involvement in glycogen storage disease type 1: Practical issues
    Ben Chehida, Amel
    Bensmail, Takoua
    Ben Rehouma, Faten
    Ben Abdelaziz, Rim
    Azzouz, Hatem
    Boudabbous, Hela
    Abdelmoula, Mohamed Slim
    Abdelhak, Sonia
    Kaabachi, Naziha
    Ben Turkia, Hadhami
    Tebib, Neji
    NEPHROLOGIE & THERAPEUTIQUE, 2015, 11 (04): : 240 - 245